We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+12.48%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.36B
AUM Growth
+$152M
Cap. Flow
+$30.3M
Cap. Flow %
1.28%
Top 10 Hldgs %
88.9%
Holding
41
New
11
Increased
4
Reduced
4
Closed
11

Top Buys

Rank Stock Value
1
AKTS
Aktis Oncology
AKTS
+$93.7M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$73.8M
3
CGON icon
CG Oncology
CGON
+$18.7M
4
RLAY icon
Relay Therapeutics
RLAY
+$17M
5
ERAS icon
Erasca
ERAS
+$10.6M

Top Sells

Rank Stock Value
1
IMNM icon
Immunome
IMNM
+$61.3M
2
MBX
MBX Biosciences
MBX
+$45.8M
3
GPCR icon
Structure Therapeutics
GPCR
+$23.3M
4
PCVX icon
Vaxcyte
PCVX
+$20.8M
5
AQST icon
Aquestive Therapeutics
AQST
+$17M

Sector Composition

Rank Sector Weight
1 Healthcare 99.22%
2 Financials 0.09%

No holdings matched the selected filter criteria.

1 2

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q1 2026 Portfolio in Review

As of Q1 2026, EcoR1 Capital held 41 positions worth $2.36B, up 6.9% from $2.2B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

EcoR1 Capital's Q1 2026 filing shows 11 new, 4 increased, 4 reduced and 11 closed positions. Its largest new stake was Aktis Oncology: 4,824,469 shares worth $86.3M. The largest sale was Immunome, an estimated $61.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • EcoR1 Capital's largest Q1 2026 buy was Aktis Oncology: 4,824,469 shares worth $86.3M.
  • EcoR1 Capital added most to Centessa Pharmaceuticals in Q1 2026, an estimated $73.8M increase.
  • EcoR1 Capital's biggest Q1 2026 reduction was MBX Biosciences, cutting an estimated $45.8M.
  • EcoR1 Capital fully exited Immunome in Q1 2026, selling an estimated $61.3M.
  • EcoR1 Capital's ten largest holdings make up 89% of its $2.36B portfolio in Q1 2026.
  • EcoR1 Capital opened 11 new positions and closed 11 in Q1 2026.
  • EcoR1 Capital's portfolio value rose 6.9% quarter-over-quarter to $2.36B.

Based on EcoR1 Capital's 13F filing for Q1 2026, filed 15 May 2026.